Previous Close | 0.0729 |
Open | 0.0729 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0729 - 0.0729 |
52 Week Range | 0.0729 - 1.1000 |
Volume | |
Avg. Volume | 426 |
Market Cap | 4.015M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), is pleased to announce that it plans to undertake a non-brokered private placement offering (the "Offering") of common shares in share capital of the Company ("Shares") to raise gross proceeds of a minimum of $3,000,000 up to $3,500,000, or such other amounts as may be determined by the Company.The Offering will close immediately after (and ...
MYND expresses the intention to acquire all the issued and outstanding shares of Tidal Psychedelics Vancouver, British Columbia--(Newsfile Corp. - March 16, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced it has entered into a non-binding memorandum of understanding ("MOU") to acquire all the issued
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or "the Company") announces the hiring of a Senior Operations and Research Manager and the resignation of a company officer.MYND is pleased to announce the hiring of Dr. Chaahat S.B Singh as the Company's Senior Operations and Research Manager. In 2019, Dr. Singh was awarded a PhD in Medical Genetics focusing on Central Nervous System (CNS) disorders at ...